Is Nemaura Medical, Inc. overvalued or undervalued?

As of 5 October 2023, Nemaura Medical, Inc. has moved from fair to attractive based on recent analysis. The company appears to be undervalued at this time. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity ratio of 0.5, indicating a solid financial position relative to its earnings and asset base.
In comparison to its peers, Dexcom, Inc. has a P/E ratio of 45.3, and Abbott Laboratories shows a P/B ratio of 4.0, highlighting that Nemaura Medical is trading at a significant discount relative to these established companies in the healthcare sector. Additionally, Nemaura's stock has outperformed the Sensex recently, reinforcing the narrative of its undervaluation.